(BRO) Brown & Brown - Overview
Stock: Insurance, Brokerage, Retail, Programs, Services
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.87% |
| Yield on Cost 5y | 1.43% |
| Yield CAGR 5y | 12.79% |
| Payout Consistency | 98.2% |
| Payout Ratio | 12.2% |
| Risk 5d forecast | |
|---|---|
| Volatility | 21.4% |
| Relative Tail Risk | -3.92% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.44 |
| Alpha | -38.19 |
| Character TTM | |
|---|---|
| Beta | 0.319 |
| Beta Downside | 0.323 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.41% |
| CAGR/Max DD | 0.21 |
Description: BRO Brown & Brown December 17, 2025
Brown & Brown, Inc. (NYSE:BRO) is a diversified insurance intermediary that sells a broad range of property-and-casualty, employee-benefits, and specialty insurance products across the United States, Canada, Ireland, the United Kingdom, and other international markets.
The Retail segment delivers direct insurance solutions-including personal lines, commercial P&C, and risk-management services-to commercial, public-sector, professional, and individual clients, handling everything from underwriting to claims processing.
The Programs segment focuses on niche professional-liability packages for dentists, lawyers, physicians, real-estate title professionals, and related fields, as well as supplemental coverages for weddings, events, cyber risk, and medical facilities, often distributed through independent agents.
The Wholesale Brokerage segment markets excess and surplus lines for both commercial and personal lines, leveraging a network of independent brokers to place high-limit and specialty risks that primary carriers typically avoid.
The Services segment provides outsourced claims administration, medical-utilization management, Medicare Set-Aside, Social Security disability advocacy, and adjusting services across workers’-compensation and all-lines liability exposures.
From a financial-performance perspective, Brown & Brown reported FY 2023 written premiums of roughly $9.7 billion-a 5 % year-over-year increase-while its combined ratio improved to 94.5 %, reflecting tighter underwriting discipline. The firm’s investment income benefited from a 5 % average U.S. Treasury yield, underscoring the sensitivity of insurers’ bottom lines to interest-rate environments. A key sector driver is the accelerating demand for cyber-liability coverage, which has been a primary source of premium growth for the Programs and Wholesale segments.
For a deeper, data-driven look at BRO’s valuation metrics and scenario analysis, you might find ValueRay’s platform worth a quick glance.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 1.05b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -1.44 > 1.0 |
| NWC/Revenue: 5.43% < 20% (prev 13.07%; Δ -7.64% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.45b > Net Income 1.05b |
| Net Debt (-118.0m) to EBITDA (2.05b): -0.06 < 3 |
| Current Ratio: 1.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (339.0m) vs 12m ago 19.37% < -2% |
| Gross Margin: 59.62% > 18% (prev 0.48%; Δ 5914 % > 0.5%) |
| Asset Turnover: 24.83% > 50% (prev 26.49%; Δ -1.67% > 0%) |
| Interest Coverage Ratio: 5.59 > 6 (EBITDA TTM 2.05b / Interest Expense TTM 301.0m) |
Altman Z'' 1.74
| A: 0.01 (Total Current Assets 8.62b - Total Current Liabilities 8.29b) / Total Assets 29.99b |
| B: 0.23 (Retained Earnings 6.99b / Total Assets 29.99b) |
| C: 0.07 (EBIT TTM 1.68b / Avg Total Assets 23.80b) |
| D: 0.42 (Book Value of Equity 7.24b / Total Liabilities 17.42b) |
| Altman-Z'' Score: 1.74 = BBB |
What is the price of BRO shares?
Over the past week, the price has changed by +2.57%, over one month by -7.87%, over three months by -3.23% and over the past year by -31.04%.
Is BRO a buy, sell or hold?
- StrongBuy: 3
- Buy: 2
- Hold: 6
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the BRO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 84.4 | 14.3% |
| Analysts Target Price | 84.4 | 14.3% |
| ValueRay Target Price | 72.3 | -2% |
BRO Fundamental Data Overview January 31, 2026
P/E Forward = 15.3374
P/S = 4.2715
P/B = 1.9308
P/EG = 4.41
Revenue TTM = 5.91b USD
EBIT TTM = 1.68b USD
EBITDA TTM = 2.05b USD
Long Term Debt = 7.65b USD (from longTermDebt, two quarters ago)
Short Term Debt = 718.0m USD (from shortTermDebt, last quarter)
Debt = 961.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -118.0m USD (from netDebt column, last quarter)
Enterprise Value = 24.50b USD (24.62b + Debt 961.0m - CCE 1.08b)
Interest Coverage Ratio = 5.59 (Ebit TTM 1.68b / Interest Expense TTM 301.0m)
EV/FCF = 16.90x (Enterprise Value 24.50b / FCF TTM 1.45b)
FCF Yield = 5.92% (FCF TTM 1.45b / Enterprise Value 24.50b)
FCF Margin = 24.54% (FCF TTM 1.45b / Revenue TTM 5.91b)
Net Margin = 17.82% (Net Income TTM 1.05b / Revenue TTM 5.91b)
Gross Margin = 59.62% ((Revenue TTM 5.91b - Cost of Revenue TTM 2.39b) / Revenue TTM)
Gross Margin QoQ = 83.82% (prev 50.62%)
Tobins Q-Ratio = 0.82 (Enterprise Value 24.50b / Total Assets 29.99b)
Interest Expense / Debt = 10.41% (Interest Expense 100.0m / Debt 961.0m)
Taxrate = 16.51% (53.0m / 321.0m)
NOPAT = 1.40b (EBIT 1.68b * (1 - 16.51%))
Current Ratio = 1.04 (Total Current Assets 8.62b / Total Current Liabilities 8.29b)
Debt / Equity = 0.08 (Debt 961.0m / totalStockholderEquity, last quarter 12.57b)
Debt / EBITDA = -0.06 (Net Debt -118.0m / EBITDA 2.05b)
Debt / FCF = -0.08 (Net Debt -118.0m / FCF TTM 1.45b)
Total Stockholder Equity = 10.84b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.42% (Net Income 1.05b / Total Assets 29.99b)
RoE = 9.71% (Net Income TTM 1.05b / Total Stockholder Equity 10.84b)
RoCE = 9.09% (EBIT 1.68b / Capital Employed (Equity 10.84b + L.T.Debt 7.65b))
RoIC = 8.45% (NOPAT 1.40b / Invested Capital 16.63b)
WACC = 7.15% (E(24.62b)/V(25.58b) * Re(7.09%) + D(961.0m)/V(25.58b) * Rd(10.41%) * (1-Tc(0.17)))
Discount Rate = 7.09% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 9.66%
[DCF Debug] Terminal Value 82.75% ; FCFF base≈1.31b ; Y1≈1.48b ; Y5≈1.98b
Fair Price DCF = 122.4 (EV 41.01b - Net Debt -118.0m = Equity 41.12b / Shares 336.0m; r=7.15% [WACC]; 5y FCF grow 14.56% → 2.90% )
EPS Correlation: 73.79 | EPS CAGR: 4.80% | SUE: 0.60 | # QB: 0
Revenue Correlation: 90.43 | Revenue CAGR: 17.75% | SUE: 0.27 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.37 | Chg30d=-0.060 | Revisions Net=-3 | Analysts=16
EPS current Year (2026-12-31): EPS=4.52 | Chg30d=-0.147 | Revisions Net=-2 | Growth EPS=+6.0% | Growth Revenue=+21.9%
EPS next Year (2027-12-31): EPS=4.98 | Chg30d=-0.196 | Revisions Net=-4 | Growth EPS=+10.2% | Growth Revenue=+6.9%